BioArctic AB (publ) (BRCTF)

18,08 +0,39 (+2,19%) Börsenschluss: 09:46AM EDT

BioArctic AB (publ)

Warfvinges vag 35
Stockholm 112 51
Sweden
46 86 95 69 30
https://www.bioarctic.se

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 88

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Gunilla Osswald Ph.D.	President & CEO	8,75M	N/A	1961
Dr. Pär Gellerfors	Co-Founder, Senior VP of Business Strategy & Director	390k	N/A	1947
Prof. Lars Lannfelt	Co-Founder, Senior VP of University Collaborations & Director	2,54M	N/A	1949
Mr. Anders Martin-Lof M.B.A., M.Sc.	Chief Financial Officer	N/A	N/A	1971
Ms. Johanna Fälting	Chief Research Officer & Head of Research	N/A	N/A	1972
Mr. Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	N/A	N/A	1959
Mr. Oskar Bosson	VP and Head of IR & Communication	N/A	N/A	1976
Mr. Leif Gallo LL.M.	General Counsel and Head of Legal & IP	N/A	N/A	1959
Mr. Harald Borgeke	Head of Public Affairs	N/A	N/A	N/A
Ms. Frida Lekander	Head of Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Corporate Governance

BioArctic AB (publ)s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.